نتائج البحث

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents (LODEFI)

• Authors : Novartis

• Source: Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI)

تفاصيل العنوان

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

• Source: A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With

تفاصيل العنوان

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2

• Source: A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in

تفاصيل العنوان

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

• Source: Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

تفاصيل العنوان

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

• Authors : Novartis

• Source: Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New

تفاصيل العنوان

Pilot Study for Patients With Poor Response to Deferasirox

• Authors : Novartis; Ellis Neufeld, Professor of Pediatrics

• Source: Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK,

تفاصيل العنوان

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

• Authors : IRCCS Burlo Garofolo; University of Genova; Antonello Di Paolo, M.D., Ph.D., Associated Professor

• Source: Identification of Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients Undergoing a Hematopoietic Stem Cell Transplant (HSCT)Maximova N, Zanon D, Pascolo

تفاصيل العنوان

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

• Authors : Gilead Sciences; Astellas Pharma Inc; Novartis

• Source: The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) StudySpellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology,

تفاصيل العنوان

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

• Authors : Erfan Nur, Principal Investigator

• Source: Low Dose Iron Chelation as TReatment of Oxidative Damage in Patients With Sickle Cell Disease: the TROS Study

تفاصيل العنوان

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

• Source: Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

تفاصيل العنوان